Clinical Trial Update: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ASP2215 (gilteritinib) to salvage chemotherapy in relapsed or refractory acute myeloid leukemia with FLT3 mutation. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3 Mutation

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: AML With FLT3 Mutation | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-14